Published April 30, 2018
Brian Tsuji, PharmD, has been promoted to the rank of Professor in the Department of Pharmacy Practice at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.
"The appointment is in recognition of his hard work, outstanding record of scholarship, contributions to further the teaching methods of the school, and service to the department, school and professional organizations nationally and internationally," said William Prescott, PharmD '02, clinical associate professor and interim-chair, pharmacy practice.
A faculty member since 2005, he has developed an independent, federally-funded research program in response to the recent spread of multidrug-resistant gram-negative bacteria. He is considered an internationally leading expert on antimicrobial pharmacology.
Tsuji has been continuously funded by the National Institutes of Health (NIH) for over a decade and is currently the Principal Investigator of $4.4M R01 grant focusing on the pharmacokinetics and pharmacodynamics of polymyxin combinations. The grant is the largest NIH grant in the history of the UB School of Pharmacy and Pharmaceutical Sciences, and the largest active R01 at UB and among departments of clinical pharmacy in the U.S. Research funded by this grant led to the ground-breaking discovery of a novel combination of three antibiotics that eradicates the first strain of highly resistant E. coli.
A prolific scholar, Tsuji has more than 85 peer-reviewed manuscripts, with over 40 papers being published in the last three years. He has given more than 60 invited oral presentations around the world. He serves on more than 15 scientific editorial and review boards and is a scientific reviewer for NIH. He has received numerous awards, including an Exceptional Scholar Young Investigator Award from the University at Buffalo (2009), the Pfizer ASPIRE Young Investigator Award in Antibacterial Research (2009), and Researcher of the Year Award from the American Clinical College of Pharmacy New York State Chapter (2008 and 2013).
He currently serves as president for the International Society of Anti-Infective Pharmacology (ISAP) and was recently co-chair of the organizing committee for the 3rd International Conference on Polymyxins in Madrid, Spain. He is also curently the co-chair and lead author for the Polymyxin Dosing Guidelines: Consensus Recommendations, which provide critical clinicial guidance on the use of polymyxin antibiotics around the globe.
He is an active member of the American Society of Microbiology, the Society of Infectious Diseases Pharmacy and the American College of Clinical Pharmacy, and is a fellow of both the Infectious Diseases Society of America and the Society of Critical Care Medicine.
Tsuji earned his BS in pharmaceutical sciences in 2001 and PharmD in 2003 from Wayne State University in Detroit. After working as a clinical pharmacist at Detroit Receiving Hospital, he completed a postdoctoral fellowship at the Detroit Medical Center and Wayne State University, after which he joined the UB School of Pharmacy and Pharmaceutical Sciences.